Contributions
Abstract: PB2105
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) are a heterogenous set of clonal stem cell neoplastic disorders defined by ineffective hematopoiesis which translates to peripheral cytopenia with one or more lineages being affected. According to WHO, MDS is classified into six distinct entities based on morphologic, quantative and qualitative evaluation of both peripheral blood and bone marrow. Flow cytometry immunophenotyping, bone marrow biopsy, cytogenetics and molecular biology offer further information relating to prognosis and treatment options. An independent prognostic factor in MDS is transfusion dependency. Higher mortality rates have, especially in low-risk patients, been related to higher transfusion frequency and consequential iron overload.
Aims
The aim of this study is to evaluate the prognostic value of transfusion requirement, anaemia severity at moment of diagnosis, chelation therapy and to estimate mortality as it relates to these factors.
Methods
We analysed data retrospectively from one hundred twenty eight patients with myelodysplastic syndrome diagnosed between January 2012 and February 2018 and we evaluated transfusion requirement, admission frequency, anaemia severity at diagnosis, chelation therapy and overall survival.
Results
Mortality rate was high, at 67% (n=86); for these patients, haemoglobin at diagnosis was 8.7, transfusion requirement median was 18, with an average of 10 admissions per patient, as opposed to a haemoglobin at diagnosis of 9.3, transfusion requirement of 19 and a number of admission of 15 for the 33% (n=42) of patients that survived. In cases where chelation therapy was needed, mortality was related to the number of transfusions administered with a median of 30 in the higher morality group and a median of 7 transfusions for the lower mortality group.
Conclusion
In conclusion, a lower haemoglobin level at diagnosis resulted in a higher mortality rate, the same as with patients with a higher transfusion requirement and post transfusion iron overload that required chelation therapy. This retrospective data supports the use of transfusion frequency as an negative prognostic indicator.
Session topic: 10. Myelodysplastic syndromes – Clinical
Keyword(s): Hemoglobin, Myelodysplasia, transfusion
Abstract: PB2105
Type: Publication Only
Background
Myelodysplastic syndromes (MDS) are a heterogenous set of clonal stem cell neoplastic disorders defined by ineffective hematopoiesis which translates to peripheral cytopenia with one or more lineages being affected. According to WHO, MDS is classified into six distinct entities based on morphologic, quantative and qualitative evaluation of both peripheral blood and bone marrow. Flow cytometry immunophenotyping, bone marrow biopsy, cytogenetics and molecular biology offer further information relating to prognosis and treatment options. An independent prognostic factor in MDS is transfusion dependency. Higher mortality rates have, especially in low-risk patients, been related to higher transfusion frequency and consequential iron overload.
Aims
The aim of this study is to evaluate the prognostic value of transfusion requirement, anaemia severity at moment of diagnosis, chelation therapy and to estimate mortality as it relates to these factors.
Methods
We analysed data retrospectively from one hundred twenty eight patients with myelodysplastic syndrome diagnosed between January 2012 and February 2018 and we evaluated transfusion requirement, admission frequency, anaemia severity at diagnosis, chelation therapy and overall survival.
Results
Mortality rate was high, at 67% (n=86); for these patients, haemoglobin at diagnosis was 8.7, transfusion requirement median was 18, with an average of 10 admissions per patient, as opposed to a haemoglobin at diagnosis of 9.3, transfusion requirement of 19 and a number of admission of 15 for the 33% (n=42) of patients that survived. In cases where chelation therapy was needed, mortality was related to the number of transfusions administered with a median of 30 in the higher morality group and a median of 7 transfusions for the lower mortality group.
Conclusion
In conclusion, a lower haemoglobin level at diagnosis resulted in a higher mortality rate, the same as with patients with a higher transfusion requirement and post transfusion iron overload that required chelation therapy. This retrospective data supports the use of transfusion frequency as an negative prognostic indicator.
Session topic: 10. Myelodysplastic syndromes – Clinical
Keyword(s): Hemoglobin, Myelodysplasia, transfusion